drugset / Trial / NCT05696795
Janus Kinase Inhibition in Sarcoidosis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the role of the oral JAK1 inhibitor, abrocitinib 200 mg once daily, for the treatment of patients with moderate to severe cutaneous sarcoidosis.
Timeline
- Start
- 2023-06-01
- Primary completion
- 2025-04-23
- Completion
- 2025-04-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abrocitinib | Small molecule | 200 mg | Oral |